标题
Incorporation of molecular characteristics into endometrial cancer management
作者
关键词
-
出版物
HISTOPATHOLOGY
Volume 76, Issue 1, Pages 52-63
出版商
Wiley
发表日期
2019-12-18
DOI
10.1111/his.14015
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma
- (2019) Mitsutake Yano et al. MODERN PATHOLOGY
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma
- (2019) Danielle C. Costigan et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma
- (2019) Heidi Britton et al. GYNECOLOGIC ONCOLOGY
- Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer
- (2019) Elke E M Peters et al. HISTOPATHOLOGY
- Lynch Syndrome Screening in Gynecological Cancers: Results of an International Survey with Recommendations for Uniform Reporting Terminology for Mismatch Repair Immunohistochemistry Results
- (2019) Neil Ryan et al. HISTOPATHOLOGY
- Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
- (2019) Bastiaan G. Wortman et al. Current Oncology Reports
- HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy
- (2019) Douglas Rottmann et al. MODERN PATHOLOGY
- p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies
- (2019) Naveena Singh et al. JOURNAL OF PATHOLOGY
- Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas
- (2019) Alicia León‐Castillo et al. JOURNAL OF PATHOLOGY
- Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
- (2018) S Kommoss et al. ANNALS OF ONCOLOGY
- Adjuvant Treatment forPOLEProofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
- (2018) Inge C. Van Gool et al. CLINICAL CANCER RESEARCH
- Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas
- (2018) Martin Köbel et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
- (2018) Amanda N. Fader et al. JOURNAL OF CLINICAL ONCOLOGY
- The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses
- (2018) Jessica McAlpine et al. JOURNAL OF PATHOLOGY
- Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
- (2018) Stephanie M de Boer et al. LANCET ONCOLOGY
- Molecular insights into the classification of high-grade endometrial carcinoma
- (2018) Yaser R. Hussein et al. PATHOLOGY
- Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
- (2018) B. G. Wortman et al. BRITISH JOURNAL OF CANCER
- Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
- (2018) Marthe M. de Jonge et al. CLINICAL CANCER RESEARCH
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer
- (2018) Antonio Travaglino et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report
- (2017) M.M. de Jonge et al. EUROPEAN JOURNAL OF CANCER
- Blinded histopathological characterisation of POLE exonuclease domain- mutant endometrial cancers: sheep in wolf's clothing
- (2017) Inge C Van Gool et al. HISTOPATHOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
- (2017) Katherine C Kurnit et al. MODERN PATHOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
- (2017) Florine A. Eggink et al. OncoImmunology
- Regression of Chemotherapy-Resistant Polymerase (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab
- (2016) A. D. Santin et al. CLINICAL CANCER RESEARCH
- Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
- (2016) Ellen Stelloo et al. CLINICAL CANCER RESEARCH
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
- (2016) Janice M. Mehnert et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2016) D. Scott McMeekin et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
- (2016) Stephanie M de Boer et al. LANCET ONCOLOGY
- Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations
- (2016) Catherine A. Shu et al. JAMA Oncology
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
- (2015) N. Colombo et al. ANNALS OF ONCOLOGY
- A clinically applicable molecular-based classification for endometrial cancers
- (2015) A Talhouk et al. BRITISH JOURNAL OF CANCER
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
- (2015) I. C. van Gool et al. CLINICAL CANCER RESEARCH
- Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials
- (2015) Tjalling Bosse et al. EUROPEAN JOURNAL OF CANCER
- Significance of Lymphovascular Space Invasion in Uterine Serous Carcinoma
- (2015) Ira Winer et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
- (2015) Ellen Stelloo et al. MODERN PATHOLOGY
- HER2-directed therapy: current treatment options for HER2-positive breast cancer
- (2015) Shahid Ahmed et al. Breast Cancer
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- HER2/neuin Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges
- (2014) Natalia Buza et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results
- (2014) T. Bosse et al. EUROPEAN JOURNAL OF CANCER
- Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
- (2014) David N. Church et al. JNCI-Journal of the National Cancer Institute
- Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma
- (2014) Yuexin Liu et al. JNCI-Journal of the National Cancer Institute
- Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
- (2013) C. Blake Gilks et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Marked heterogeneity ofHER2/NEUgene amplification in endometrial serous carcinoma
- (2013) Natalia Buza et al. GENES CHROMOSOMES & CANCER
- Impact of lymphovascular space invasion on a nomogram for predicting lymph node metastasis in endometrial cancer
- (2013) Martin Koskas et al. GYNECOLOGIC ONCOLOGY
- Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
- (2013) Natalia Buza et al. MODERN PATHOLOGY
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Endometrial Carcinomas
- (2011) Carla Bartosch et al. ADVANCES IN ANATOMIC PATHOLOGY
- Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer
- (2011) Saketh R. Guntupalli et al. GYNECOLOGIC ONCOLOGY
- External Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma—A Prospective Randomized Study
- (2011) Bengt Sorbe et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–Results from two randomised studies
- (2010) Thomas Hogberg et al. EUROPEAN JOURNAL OF CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
- (2010) RA Nout et al. LANCET
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
- (2009) Gini F. Fleming et al. GYNECOLOGIC ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started